MK-7264

**MK-7264**
法律規範狀態
法律規範	美：Investigational New Drug;
識別資訊
	IUPAC命名法 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide; ;
CAS號	1015787-98-0
PubChem CID	24764487;
DrugBank	DB15097;
ChemSpider	58828660;
UNII	6K6L7E3F1L;
KEGG	D11349;
ChEMBL	ChEMBL3716057;
ECHA InfoCard	100.258.106
化學資訊
化學式	C14H19N5O4S
摩爾質量	353.4
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC;
	InChI InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19); Key:HLWURFKMDLAKOD-UHFFFAOYSA-N;

MK-7264（英語：Gefapixant）是一種磺胺類藥物，作為嘌呤 P2X受體P2RX3（英語：P2RX3）的拮抗劑，可用於治療慢性咳嗽（英語：chronic cough）^[1]^[2]^[3]。

參考文獻

^ Muccino D, Green S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulmonary Pharmacology & Therapeutics. June 2019, 56 ( ): 75–78. PMID 30880151. doi:10.1016/j.pupt.2019.03.006.
^ Richards D, Gever JR, Ford AP, Fountain SJ. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. British Journal of Pharmacology. July 2019, 176 (13): 2279–2291. PMC 6555852 . PMID 30927255. doi:10.1111/bph.14677.
^ Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, Lambertucci C. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Expert Opinion on Therapeutic Patents. December 2019, 29 (12): 943–963. PMID 31726893. doi:10.1080/13543776.2019.1693542.

這是一篇關於呼吸系統的藥理學小作品。你可以透過編輯或修訂擴充其內容。